Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.31 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.31 |
| ▸ | CYP46A1 | Q9Y6A2 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798873 | 0.80 | CYP11B2 (0.39) | CYP17A1CYP11B2P2RX7CYP11B1 | |
| SCHEMBL15467686 | 0.77 | CYP17A1 (0.34) | CYP17A1CYP11B2P2RX7CYP11B1 | |
| SCHEMBL793672 | 0.76 | HTR2C (0.35) | CYP17A1CYP11B2P2RX7CYP11B1C5AR1 | |
| SCHEMBL793691 | 0.76 | P2RX7 (0.40) | CYP17A1CYP11B2P2RX7CYP11B1 | |
| SCHEMBL12467032 | 0.72 | CYP11B2 (0.52) | CYP17A1CYP11B2P2RX7CYP11B1 | |
| SCHEMBL793787 | 0.71 | CYP11B2 (0.35) | CYP17A1CYP11B2CYP11B1 | |
| SCHEMBL794188 | 0.70 | PDE4A (0.36) | CYP17A1CYP11B2P2RX7 | |
| SCHEMBL15471806 | 0.70 | OPRM1 (0.36) | CYP17A1CYP11B2P2RX7CYP11B1C5AR1 | |
| SCHEMBL807907 | 0.69 | CYP11B2 (0.43) | CYP17A1CYP11B2CYP11B1 | |
| SCHEMBL807995 | 0.69 | CYP11B2 (0.42) | CYP11B2P2RX7CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | CYP17A1 1/4885CYP11B2 30/4885P2RX7 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.